- Home
- LUNG vs PROK Comparison
LUNG vs PROK Comparison
Compare LUNG & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- PROK
- Stock Information
- Founded
- LUNG 1995
- PROK 2015
- Country
- LUNG United States
- PROK United States
- Employees
- LUNG N/A
- PROK N/A
- Industry
- LUNG Industrial Specialties
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LUNG Health Care
- PROK Health Care
- Exchange
- LUNG Nasdaq
- PROK Nasdaq
- Market Cap
- LUNG 296.1M
- PROK 186.8M
- IPO Year
- LUNG 2020
- PROK N/A
- Fundamental
- Price
- LUNG $7.10
- PROK $0.98
- Analyst Decision
- LUNG Strong Buy
- PROK Buy
- Analyst Count
- LUNG 7
- PROK 4
- Target Price
- LUNG $12.64
- PROK $5.00
- AVG Volume (30 Days)
- LUNG 483.0K
- PROK 574.5K
- Earning Date
- LUNG 04-30-2025
- PROK 03-21-2025
- Dividend Yield
- LUNG N/A
- PROK N/A
- EPS Growth
- LUNG N/A
- PROK N/A
- EPS
- LUNG N/A
- PROK N/A
- Revenue
- LUNG $83,789,000.00
- PROK N/A
- Revenue This Year
- LUNG $17.96
- PROK N/A
- Revenue Next Year
- LUNG $18.35
- PROK N/A
- P/E Ratio
- LUNG N/A
- PROK N/A
- Revenue Growth
- LUNG 22.01
- PROK N/A
- 52 Week Low
- LUNG $5.46
- PROK $0.94
- 52 Week High
- LUNG $10.01
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- LUNG 46.79
- PROK 26.06
- Support Level
- LUNG $7.07
- PROK $0.94
- Resistance Level
- LUNG $7.65
- PROK $1.08
- Average True Range (ATR)
- LUNG 0.67
- PROK 0.11
- MACD
- LUNG -0.19
- PROK -0.02
- Stochastic Oscillator
- LUNG 12.93
- PROK 6.78
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.